Skip to main content

FDA Approvals

Retevmo Receives New FDA Indication for Advanced Solid Tumors with RET Fusion

Pemazyre Receives New Indication for FGFR1-Positive Myeloid/Lymphoid Neoplasms

Imbruvica Now Also Indicated for Children with Chronic Graft-versus-Host Disease

Lytgobi FDA Approved for Intrahepatic Cholangiocarcinoma with FGFR2 Fusion

Vegzelma a New Biosimilar FDA Approved for the Treatment of 6 Types of Cancer

Enhertu First FDA-Approved Drug for HER2-Positive Non–Small-Cell Lung Cancer

Enhertu First FDA-Approved Treatment for HER2-Low Breast Cancer

Breyanzi Now FDA Approved for Second-Line Treatment of Large B-Cell Lymphoma

Tafinlar plus Mekinist First Tumor-Agnostic Therapy Approved for Any Unresectable or Metastatic Solid Tumors with BRAF Mutation

Xalkori Now FDA Approved for the Treatment of ALK-Positive Inflammatory Myofibroblastic Tumor

Page 5 of 21
Results 41 - 50 of 202